Literature DB >> 31763675

DDAH-2 alleviates contrast medium iopromide-induced acute kidney injury through nitric oxide synthase.

Heng-Huei Lin1, Tzong-Shyuan Lee2, Shing-Jong Lin3,4,5, Yi-Chen Yeh4,6, Tse-Min Lu3,4,7, Chiao-Po Hsu1,4.   

Abstract

BACKGROUND: Contrast medium-induced acute kidney injury (CI-AKI) is one of the most common causes of hospital-acquired acute renal failure. However, the pathogenesis of CI-AKI remains unclear. Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide synthase (NOS) inhibitor that is largely metabolised by dimethylarginine dimethylaminohydroxylase (DDAH) in humans. Two isoforms of DDAH exist, namely, DDAH-1 and DDAH-2. In the present study, we examined whether the DDAH-2/ADMA/NOS pathway is involved in the pathogenesis of CI-AKI. METHODS AND
RESULTS: Exposure to the contrast medium iopromide led to increase in creatinine and blood urea nitrogen (BUN) levels, accumulation of ADMA, increase in reactive oxygen species (ROS) generation, and an inflammatory response in mice kidney tissue. The injection of adenovirus-harbouring DDAH-2 lowered renal ADMA levels and had a reno-protective effect against contrast-medium injury by decreasing cell apoptosis, ROS, and fibrosis. By contrast, contrast medium-induced renal injury was exacerbated in heterozygous DDAH-2 knockout mice. In the in vitro study, overexpression of DDAH-2 increased the levels of nitrite and intracellular cGMP, while the DDAH-2 knockdown induced the opposite effect. These findings were also observed in the in vivo sample.
CONCLUSIONS: Our findings provide the first evidence that the DDAH-2/ADMA/NOS pathway is involved in the pathogenesis of CI-AKI and that the protective effect of DDAH-2 probably arises from the modulation of NOS activity, oxidative stress, and the inflammatory process.
© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  asymmetric dimethylarginine; contrast medium; contrast-induced acute kidney injury; dimethylarginine dimethylaminohydroxylase; nitric oxide synthases

Mesh:

Substances:

Year:  2019        PMID: 31763675     DOI: 10.1042/CS20190455

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  6 in total

1.  A Novel Antioxidant Protects Against Contrast Medium-Induced Acute Kidney Injury in Rats.

Authors:  Shuo Huang; Yanyan Tang; Tianjun Liu; Ning Zhang; Xueyan Yang; Dingwei Yang; Ge Hong
Journal:  Front Pharmacol       Date:  2020-11-27       Impact factor: 5.810

Review 2.  Nanodrugs alleviate acute kidney injury: Manipulate RONS at kidney.

Authors:  Qiaohui Chen; Yayun Nan; Yuqi Yang; Zuoxiu Xiao; Min Liu; Jia Huang; Yuting Xiang; Xingyu Long; Tianjiao Zhao; Xiaoyuan Wang; Qiong Huang; Kelong Ai
Journal:  Bioact Mater       Date:  2022-09-29

3.  Asymmetric dimethylarginine (ADMA) accelerates renal cell fibrosis under high glucose condition through NOX4/ROS/ERK signaling pathway.

Authors:  Isaivani Jayachandran; Saravanakumar Sundararajan; Saravanakumar Venkatesan; Sairaj Paadukaana; Muthuswamy Balasubramanyam; Viswanathan Mohan; Nagaraj Manickam
Journal:  Sci Rep       Date:  2020-09-29       Impact factor: 4.379

Review 4.  The Pathophysiology and the Management of Radiocontrast-Induced Nephropathy.

Authors:  Eunjung Cho; Gang-Jee Ko
Journal:  Diagnostics (Basel)       Date:  2022-01-12

5.  Divergent Dimethylarginine Dimethylaminohydrolase Isoenzyme Expression in the Central Nervous System.

Authors:  Alena A Kozlova; Vinitha N Ragavan; Roman N Rodionov; Nadine Bernhardt; Natalia Jarzebska; Iana V Lukianova; Anastasia E Bikmurzina; Elena Rubets; Toshiko Suzuki-Yamamoto; Masumi Kimoto; Arduino A Mangoni; Raul R Gainetdinov; Norbert Weiss; Michael Bauer; Alexander G Markov
Journal:  Cell Mol Neurobiol       Date:  2021-05-20       Impact factor: 4.231

6.  Renal asymmetric dimethylarginine inhibits fibrosis.

Authors:  Ming Wu; Meijie Yuan; Yanzhe Wang; Bo Tan; Di Huang; Chen Wang; Yun Zou; Chaoyang Ye
Journal:  FEBS Open Bio       Date:  2020-08-30       Impact factor: 2.792

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.